Abstract
The Australian multicentre trial of streptokinase in acute myocardial infarction has now been concluded. In all, 376 patients were treated with streptokinase followed by heparin and warfarin, and 371 received anticoagulants only. All patients were followed for 12 months. There was no significant difference in mortality (13$md6% v. 17$md0%; χ2 = 1$md69).